S
Sean P. Arlauckas
Researcher at Harvard University
Publications - 20
Citations - 2511
Sean P. Arlauckas is an academic researcher from Harvard University. The author has contributed to research in topics: Immunotherapy & Cancer immunotherapy. The author has an hindex of 12, co-authored 19 publications receiving 1519 citations. Previous affiliations of Sean P. Arlauckas include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.
Christopher B. Rodell,Sean P. Arlauckas,Michael F. Cuccarese,Christopher Garris,Ran Li,Maaz S. Ahmed,Rainer H. Kohler,Mikael J. Pittet,Ralph Weissleder +8 more
TL;DR: The ability of rationally engineered drug–nanoparticle combinations to efficiently modulate tumour-associated macrophages for cancer immunotherapy is demonstrated and R848, an agonist of the toll-like receptors TLR7 and TLR8 identified in a morphometric-based screen, is a potent driver of the M1 phenotype in vitro.
Journal ArticleDOI
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Christopher Garris,Sean P. Arlauckas,Rainer H. Kohler,Marcel P. Trefny,Seth B. Garren,Cecile Piot,Camilla Engblom,Christina Pfirschke,Marie Siwicki,Jeremy Gungabeesoon,Gordon J. Freeman,Sarah Warren,SuFey Ong,Erica Browning,Christopher G. Twitty,Robert H. Pierce,Mai H. Le,Alain Algazi,Adil Daud,Sara I. Pai,Alfred Zippelius,Ralph Weissleder,Mikael J. Pittet +22 more
TL;DR: It is found that activating the non‐canonical NF‐&kgr;B transcription factor pathway amplified IL‐12‐producing DCs and sensitized tumors to anti‐PD‐1 treatment, suggesting a therapeutic strategy to improve responses to checkpoint blockade.
Journal ArticleDOI
In Vivo Imaging Reveals a Tumor-Associated Macrophage-Mediated Resistance Pathway in anti-PD-1 Therapy
Sean P. Arlauckas,Christopher Garris,Rainer H. Kohler,Maya Kitaoka,Michael F. Cuccarese,Katherine S. Yang,Miles A. Miller,Jonathan C. T. Carlson,Gordon J. Freeman,Robert M. Anthony,Ralph Weissleder,Mikael J. Pittet +11 more
TL;DR: In vivo imaging is used to uncover the fate and activity of aPD-1 mAbs and identify specific Fc/FcγR interactions that can be modulated to improve checkpoint blockade therapy.
Journal ArticleDOI
IRF3 and type I interferons fuel a fatal response to myocardial infarction.
Kevin R. King,Aaron D. Aguirre,Yu-Xiang Ye,Yuan Sun,Jason D. Roh,Richard P. Ng,Rainer H. Kohler,Sean P. Arlauckas,Yoshiko Iwamoto,Andrej J. Savol,Ruslan I. Sadreyev,Mark J. S. Kelly,Timothy P. Fitzgibbons,Katherine A. Fitzgerald,Timothy J. Mitchison,Peter Libby,Matthias Nahrendorf,Ralph Weissleder +17 more
TL;DR: It is shown that ischemic cell death and uptake of cell debris by macrophages in the heart fuel a fatal response to MI by activating IRF3 and type I IFN production.
Journal ArticleDOI
Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages.
Sean P. Arlauckas,Seth B. Garren,Christopher Garris,Rainer H. Kohler,Juhyun Oh,Mikael J. Pittet,Ralph Weissleder +6 more
TL;DR: This research shows how powerful complementary single cell analytical approaches can be used to improve the understanding of drug action in vivo.